the COVACTA Trial

Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia

Retrieved on: 
Thursday, March 11, 2021
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Health sciences, Drugs, Orphan drugs, Health, Tocilizumab, Remdesivir, Coronavirus disease, TIMI, COVID-19 drug repurposing research, the REMDACTA Trial, the COVACTA Trial, the EMPACTA Trial, Actemra, Genentech

This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care.

Key Points: 
  • This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care.
  • The full results of the trial will be submitted for publication in a peer-reviewed journal later this year.
  • Veklury is contraindicated in patients who are allergic to Veklury or any of its components.
  • REMDACTA is a two-armed global Phase III, randomized, double-blind, multicenter study (REMDACTA, NCT04409262) to evaluate the efficacy and safety of Actemra plus Veklury, versus placebo plus Veklury in hospitalized patients with severe COVID-19 pneumonia receiving standard of care.

Genentech Provides an Update on the Phase III COVACTA Trial of Actemra in Hospitalized Patients With Severe COVID-19 Associated Pneumonia

Retrieved on: 
Wednesday, July 29, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Health, Clinical research, Medical research, Articles, Design of experiments, Drug discovery, Pharmaceutical industry, Placebo-controlled study, Placebo, Clinical trial, Coronavirus disease, Clazakizumab, the COVACTA Trial, Actemra, Genentech

COVACTA evaluated the safety and efficacy of intravenous Actemra added to standard-of-care treatment and compared to treatment with placebo plus standard of care.

Key Points: 
  • COVACTA evaluated the safety and efficacy of intravenous Actemra added to standard-of-care treatment and compared to treatment with placebo plus standard of care.
  • The COVACTA trial is the first global, randomized, double-blind, placebo-controlled Phase III study to investigate Actemra in adult patients hospitalized with severe COVID-19 associated pneumonia, with study locations in the United States, Canada and Europe.
  • Time to hospital discharge or ready to discharge was shorter in patients treated with Actemra than those treated with placebo.
  • In addition to COVACTA, Genentech has initiated several studies to further investigate Actemra as a potential treatment for patients with COVID-19 associated pneumonia, including two Phase III clinical trials, REMDACTA and EMPACTA, as well as the Phase II MARIPOSA trial.